One day after Sandoz and Amgen announced European launches of their biosimilar adalimumab products referencing Humira, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi.
One day after Sandoz and Amgen announced European launches of their biosimilar adalimumab products referencing Humira, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi. According to a company statement, the drug will become available today in major EU markets, though the company did not specify which nations would be first to receive access to the drug.
“The launch of Imraldi marks what we believe to be a landmark moment for Biogen and Samsung Bioepis and for European healthcare systems,” said Sang-Jin Pak, chief operating officer of Samsung Bioepis. “We hope Imraldi will play an important role widening choice and increasing competition in one of the most high-value areas of the biopharmaceuticals market.”
Imraldi’s launch marks Samsung Bioepis’ third EU market entry with an anti—tumor necrosis factor therapy; the company previously launched Benepali, an etanercept biosimilar, and Flixabi, an infliximab biosimilar.
Imraldi was approved in Europe in 2017 on the basis of a randomized, double-blind, 52-week phase 3 study in which 544 patients with moderate to severe rheumatoid arthritis for whom methotrexate was insufficient were randomized to receive either the biosimilar or the reference Humira.
At week 24, response rate for the American College of Rheumatology’s criteria for 20% improvement was 72.4% in the biosimilar arm versus 72.2% in the reference arm. Additionally, the safety profile of Imraldi was comparable to the reference up to week 24. At that timepoint, 254 patients receiving the reference product were randomized 1:1 to either continue to take reference adalimumab or switch to the biosimilar, while the original 254 patients taking Imraldi continued to receive the biosimilar.
The efficacy, safety, and immunogenicity profiles were comparable between all 3 treatment groups till week 52, and there were no treatment emergent issues or clinically-relevant immunogenicity precipitated by the switch.
Imraldi is also under the FDA’s consideration for US approval; in September 2018, Samsung Bioepis announced that the FDA had accepted a Biologics License Application for the drug.
Two approved adalimumab biosimilars are yet to launch in the European Union: Mylan’s Hulio and Boehringer Ingelheim’s Cyltezo. Neither developer has announced a target launch date for its product.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).